(NASDAQ: SLN) Silence Therapeutics's forecast annual revenue growth rate of 61.09% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Silence Therapeutics's revenue in 2025 is $43,258,000.On average, 4 Wall Street analysts forecast SLN's revenue for 2025 to be $5,700,539,716, with the lowest SLN revenue forecast at $599,281,333, and the highest SLN revenue forecast at $15,225,712,733. On average, 4 Wall Street analysts forecast SLN's revenue for 2026 to be $3,355,550,443, with the lowest SLN revenue forecast at $575,196,740, and the highest SLN revenue forecast at $6,763,520,293.
In 2027, SLN is forecast to generate $30,540,255,110 in revenue, with the lowest revenue forecast at $2,683,306,962 and the highest revenue forecast at $103,422,074,020.